Search

A patent application titled "Ecg Characteristics Assessment" has been published online by the US Patent and Trademark Office. The patent application, filed by inventors Jaeho Kim and Joseph L. Sullivan, describes a method and system for monitoring a patient's heart using a wearable cardioverter defibrillator (WCD) system. The WCD system includes a support structure, a processor, at least three sensing electrodes, and a discharge circuit. The processor analyzes heart data obtained from the sensing electrodes and compares it to a consistency threshold to perform a rhythm analysis. The patent application was assigned to West Affum Holdings DAC. [Extracted from the article]

A patent has been issued for systems and methods of integrating ambulatory medical devices with hospital medical devices. The patent, assigned to ZOLL Medical Corporation, describes how ambulatory medical devices can store patient data that is useful to hospital practitioners. The devices can establish secure communication sessions with hospital medical devices, transmit patient data, and receive instructions for treatment or alerts regarding patient conditions. This integration can improve patient care and allow for the construction of a patient dashboard summarizing the patient's condition over time. [Extracted from the article]

A recent report discusses research on early ventricular arrhythmias (EVAs) after left ventricular assist device (LVAD) implantation. The study found that EVAs are a common complication after LVAD implantation and are associated with an increased risk of 30-day mortality. Risk factors for EVAs include a history of end-stage renal disease, preoperative electrical storm, and previous implantable cardiac defibrillator therapy. The study suggests that further research is needed to better understand the incidence and prognostic implications of EVAs in patients with LVAD. [Extracted from the article]

Inventor Cheng, Ya-Jian has filed a patent application for a medical system that utilizes machine learning to detect changes in a patient's cardiac health. The system incorporates implantable or wearable devices that collect data on the patient's cardiac activity, such as electrocardiogram (ECG) signals. This data is then analyzed using a modular machine learning architecture to identify various cardiac events, including arrhythmias. The system aims to enhance event detection accuracy, aid clinicians in diagnosis and treatment, and potentially prevent cardiac events. Additionally, the system can benefit from remote monitoring services, allowing for updates to be sent to the devices without requiring a complete overhaul of the machine learning architecture. The patent application also provides information on the specific types of cardiac arrhythmias that can be detected by the system. [Extracted from the article]

A recent study conducted by the University of Duisburg-Essen examined the effectiveness and safety of oral anticoagulation in patients with device-detected atrial fibrillation (AF) and a prior stroke or transient ischemic attack (TIA). The study found that there was no significant difference in outcomes between patients who received anticoagulation and those who did not. The rate of stroke was lower than expected in both groups, and there were more major bleeding events in patients who received anticoagulation. The study suggests that anticoagulation may have ambiguous effects in this patient population. [Extracted from the article]

A study led by the Duke Clinical Research Institute found that wearable, long-term continuous heart monitors helped identify 52% more cases of atrial fibrillation compared to usual care. However, this increase in diagnosis did not lead to a reduction in hospitalizations due to stroke. The study, which enrolled approximately 12,000 patients in the U.S., was halted early due to the COVID pandemic and did not have enough participants to establish definitive results about stroke. The researchers emphasized the need for further evidence to determine if systematic screening for atrial fibrillation can lead to subsequent treatment and lower the risk of stroke. [Extracted from the article]

A study presented at the ESC Congress 2024 in London compared the effectiveness of cryoballoon (CB) ablation and radiofrequency (RF) ablation in heart failure patients with atrial fibrillation (AF). The study found that CB ablation was as effective as RF ablation in reducing recurrences of AF and atrial tachycardia at one year. CB ablation also had the benefit of shorter procedure time and less fluid volume, potentially reducing the risk of worsening heart failure. The study concluded that CB ablation should be considered as a simplified and effective procedure for treating AF in most heart failure patients. [Extracted from the article]

A study presented at the ESC Congress 2024 in London suggests that telemedicine support for village doctors in rural China can significantly reduce the risk of cardiovascular death in patients with atrial fibrillation (AF) by 50%. AF is a common heart rhythm disorder and a leading cause of preventable ischaemic stroke in China. The study involved 1,039 adults aged 65 or older with AF, and the intervention group, which received telemedicine support from AF specialists, showed higher rates of meeting the criteria for integrated AF care and lower rates of cardiovascular death, stroke, and hospitalization compared to the control group. The findings indicate that telemedicine-based interventions can improve AF management in low-resource settings and could be scaled up in rural China and other countries with limited healthcare access. [Extracted from the article]

The WEAR-AF study is a clinical trial that aims to evaluate the effectiveness of wearable technology, such as smartwatches with electrocardiogram capabilities, in detecting and managing atrial fibrillation (AF). Participants in the study will be individuals diagnosed with or at high risk for AF. The study will track the accuracy of AF detection, patient adherence to monitoring, and the impact on clinical outcomes, including stroke prevention and quality of life. The findings from this study are expected to contribute to the integration of wearable technology into routine clinical practice for AF management. [Extracted from the article]

A patent application has been submitted for a new method of determining long-term heart rates from wearable cardioverter defibrillator (WCD) systems. The WCD system includes a harness or garment with electronic components, such as a defibrillator and electrodes, that monitor the patient's electrocardiogram (ECG). The new method involves analyzing the stored ECG signal to assist in long-term heart rate monitoring, using special filtering techniques to remove short-term variations and indication techniques to indicate when the ECG signal is unreliable. The patent application was filed by inventors from Washington and the assignee is West Affum Holdings Dac in Dublin, Ireland. [Extracted from the article]

A patent application has been submitted for a medical support system that utilizes a wearable device to collect data on a patient during a medical event. This system generates situation reports that contain crucial health information for individuals assisting the patient. The reports can be easily accessed through QR codes or RFID signals, allowing for quick and effective care for patients in medical emergencies, especially those occurring outside of medical facilities. The wearable device collects patient data, identifies medical events, and generates a situation report that can be accessed through a webpage using Bluetooth low energy (BLE) connection, tailored to the support person's level of expertise. [Extracted from the article]

A patent application has been submitted for a computer-based method of modeling a person's heart. This method involves using medical image data to create multiple personalized heart models with different properties. Simulations of the heart's electrical activity are then performed on each model, and the results are used to generate data. This method can be used to predict and assess the risk of arrhythmic activity in the heart, providing valuable clinical information for diagnosis and evaluation. The system also includes a user interface for visualizing the simulation results. [Extracted from the article]

A patent has been issued for a catheter sensing and irrigating system developed by Affera Inc. The system is designed to safely create wide and deep lesions for the treatment of cardiac arrhythmias. It includes an expandable ablation electrode that allows for the flow of irrigation fluid and blood, effectively cooling the electrode during treatment. The system also features a deformable electrode and multiple sensors to accurately detect contact between the electrode and tissue. The patent provides detailed descriptions of the catheter's components and their functions. [Extracted from the article]

A study conducted by Universitas Padjadjaran in Indonesia aimed to determine the prevalence of atrial fibrillation (AF) in various cities using a smartphone-based diagnosis. The study enrolled 9,773 subjects and found that the prevalence of AF reported by the device and cardiologists was 3.2% and 3.5%, respectively. The majority of subjects were at low risk for stroke or systemic thromboembolism, and the prevalence of risk factors such as heart failure, hypertension, diabetes, and history of stroke among AF patients were also reported. The study concluded that the prevalence of AF in referral hospitals in Indonesia based on smartphone diagnosis is 3.2%. [Extracted from the article]

A recent systematic review and meta-analysis conducted by researchers from the University of Campania in Italy evaluated the effectiveness and safety of dexmedetomidine as adjunctive therapy for the treatment of alcohol withdrawal syndrome (AWS). The study found that dexmedetomidine was not more effective than standard therapy in reducing the risk of tracheal intubation in AWS patients. Additionally, dexmedetomidine was found to significantly increase the risk of bradycardia compared to sedative therapy. However, there was no significant difference in the occurrence of hypotension between patients who received dexmedetomidine and those who did not. These findings suggest that dexmedetomidine may not be a preferable alternative to benzodiazepines for the treatment of AWS. [Extracted from the article]

A recent study conducted at Rush University Medical Center provides an update on the understanding and management of atrial fibrillation (AF). The study highlights that while progress has been made in non-pharmacologic treatments for AF, there is still room for improvement. The researchers conducted a narrative review, analyzing various clinical trials, meta-analyses, and other relevant studies to explore the risks, benefits, and alternatives to catheter ablation for AF management. The study concludes that the Cox-maze surgical approach remains the most effective non-pharmacological treatment for AF, while hybrid ablation, combining surgical and catheter ablation techniques, is a promising option for persistent AF. [Extracted from the article]

A new report discusses research findings on atrial fibrillation, a type of cardiac arrhythmia. The study compared the outcomes of minimally invasive concomitant mitral and tricuspid valve surgery with surgical ablation using two different approaches: right mini-thoracotomy and sternotomy. The research found that there were no significant differences in long-term outcomes between the two approaches, suggesting that right mini-thoracotomy could be a reasonable option. However, patients with atrial fibrillation high-risk factors may have better ablation outcomes with sternotomy. The study was conducted at Dong-A University Hospital in Busan, South Korea. [Extracted from the article]

This document provides information about a clinical study comparing two different catheter ablation technologies for treating atrial fibrillation. The study will involve participants who will undergo two different procedures and complete quality of life questionnaires over a period of four months. The two arms of the study will compare pulse field ablation and cryoablation. The study is currently not recruiting participants and is expected to be completed by February 2026. The document also includes eligibility criteria and contact information for the study. [Extracted from the article]

A study conducted by researchers at Brown University in Providence, Rhode Island, aimed to identify risk factors for major adverse cardiovascular events (MACE) and symptomatic bleeding in patients with atrial fibrillation (AF) undergoing elective procedures. The study analyzed data from the Bridge Trial and found that pre-procedure clopidogrel use and a CHA2DS2-VASc score of 5 or higher were identified as risk factors for MACE, while bridge therapy, renal disease, post-procedure aspirin use, post-procedure nonsteroidal anti-inflammatory drug use (excluding aspirin), and major surgery were identified as risk factors for symptomatic bleeding. The researchers hope that these findings will help guide perioperative decisions to reduce the risk of adverse outcomes. [Extracted from the article]

A recent study conducted at HagaZiekenhuis has investigated the use of continuous intravenous magnesium sulphate administration to prevent postoperative atrial fibrillation (POAF) in patients undergoing cardiac surgery. POAF is a common and potentially serious complication following cardiac surgery, and hypomagnesaemia is also common in these patients. The study aims to assess the effectiveness of magnesium supplementation in preventing POAF compared to a placebo. The trial will include 530 patients and the primary outcome measure is the incidence of POAF within the first 7 days following surgery. This research may provide crucial evidence for the prevention of POAF and reducing adverse events in patients undergoing cardiac surgery. [Extracted from the article]

A patent application has been submitted for a new method of assessing the hemodynamic effects of cardiac arrhythmias using signals sensed by an implantable device. The current technology for implantable cardioverter/defibrillators (ICDs) can sometimes result in inappropriate shocks, but this new method aims to minimize these shocks by evaluating hemodynamics during arrhythmias using non-barometric signals. The system described in the patent application includes optical fibers, an optical source, a receiver, and a processor to analyze the signals and determine hemodynamic stability. The application provides technical details about the system and its components. [Extracted from the article]

A patent application has been submitted for a detailed alarm messaging system for wearable cardioverter defibrillators (WCDs). The WCD continuously monitors a patient's heart and delivers an electric shock if certain arrhythmias are detected. The proposed system would alert the user of the WCD through a remote device, personalized with the user's health and location data. It would also allow for troubleshooting and emergency alerts, including contacting emergency personnel and the user's attending physician. The patent application was filed by inventors from Washington state and the assignee is West Affum Holdings Dac. [Extracted from the article]

A study conducted at the IRCCS Humanitas Research Hospital investigated the incidence and predictors of postoperative atrial fibrillation (POAF) in 53,387 patients who underwent major surgical procedures between January 2016 and January 2020. The study found that POAF occurred in 1.1% of patients, with a mean latency of 3.4 days after surgery. Lung and cardiovascular surgery had the highest risk of POAF, and higher levels of C-reactive protein (CRP) were associated with an increased risk of POAF. The study suggests that inflammation may play a significant role in the development of POAF. [Extracted from the article]

A recent study conducted by researchers at the Division of Cardiology evaluated the efficacy of two algorithms, the Ventricular Pace Suppression algorithm (VpS) and the Intrinsic Rhythm Support plus algorithm (IRSplus), in patients with symptomatic sinus node dysfunction (SND) who received a dual-chamber pacemaker. The study, conducted in 11 tertiary hospitals in South Korea, found that both algorithms were effective in reducing unnecessary ventricular pacing. The algorithms were particularly effective in patients with a paced AV delay (PAVD) of 300 ms or less. No occurrences of heart failure or atrial fibrillation were observed during the study period. The researchers concluded that the VpS and IRSplus algorithms are safe and effective in minimizing unnecessary ventricular pacing in patients with SND. [Extracted from the article]

A recent report from NYC Health + Hospitals discusses a case of ectopic atrial bradycardia associated with the use of fludarabine, a chemotherapeutic agent. The report highlights that while fludarabine is generally considered safe, rare cases of cardiotoxic side effects can occur. The case involved a 30-year-old woman undergoing conditioning for a stem cell transplantation, who experienced bradycardia after receiving fludarabine. The bradycardia resolved with supportive therapy and completion of the fludarabine infusion. The researchers emphasize the importance of recognizing this rare side effect of fludarabine. [Extracted from the article]

The US Patent and Trademark Office has published a patent application for a temporary pacing lead called the "Curled Shaft Temporary Pacing Lead." This lead aims to address the limitations of current standard leads by featuring a curled shaft with multiple electrode sites, allowing for easy placement and contact with the heart's surface. The invention aims to provide atraumatic placement without the need for fluoroscopy or echocardiographic guidance. The lead can be easily stabilized, repositioned, and removed once it is no longer needed. The patent application provides detailed descriptions of the lead's design and features, including its ability to deliver electrical signals to the heart and its compatibility with different electrode configurations. [Extracted from the article]

A patent application has been submitted for a new method called "Cardiac Pulsed Field Ablation" that aims to treat cardiac tissue. The method involves delivering a pulse train of energy to the tissue, which includes at least 60 pulses, with specific delays and pulse widths. The system includes a medical device with electrodes and a generator to deliver the pulse train. The method aims to treat arrhythmias by creating lesions that compartmentalize aberrant pathways and promote organized signal conduction. The application addresses potential drawbacks of current treatments, such as collateral damage and extended treatment time. [Extracted from the article]

A new report from the University of Florida presents fresh data on the outcomes of patients with systolic heart failure who underwent sympathectomy for ventricular arrhythmia. The study aimed to evaluate the medical co-morbidities and outcomes of these patients. The results showed that cardiac sympathetic denervation (CSD) performed for refractory ventricular arrhythmia had favorable survival in patients with systolic heart failure. This study lays the groundwork for further analysis of the potential survival benefits of CSD in this patient group. [Extracted from the article]

A patent application has been filed for a new system that aims to improve the charging process of defibrillators, such as automated external defibrillators (AEDs). The system would analyze electrocardiogram (ECG) signals from a patient while chest compressions are being administered and selectively charge the defibrillator based on the analysis. This would make defibrillation readily available to the operator and extend the battery life of the device. The system would also determine whether a defibrillating shock is suitable therapy before providing the shock. The goal is to improve the effectiveness and convenience of defibrillators while ensuring patient safety. [Extracted from the article]

A patent application has been submitted for a software tool that uses environmental factors and data from implantable medical devices to predict the risk of heart failure in patients. The software tool takes into account diagnostic parameters monitored over time, such as heart rate and activity levels, as well as environmental factors like particulate matter exposure and temperature. By providing more accurate predictions and treatment recommendations, this tool has the potential to improve patient outcomes and reduce reliance on subjective measures in the diagnosis process. The patent application was filed by a group of inventors from Minnesota. [Extracted from the article]

A study conducted by Uppsala University has found that bradycardia, a slow heart rate, is more common among well-trained male athletes compared to the general population. The study examined the association between endurance training and the incidence of bradycardia and pacemaker implantations. Male skiers who completed more races and had faster finishing times had a higher incidence of bradycardia and pacemaker implantations. However, there was no significant difference in the incidence of bradycardia and pacemaker implantations among female skiers compared to female nonskiers. The study suggests that bradycardia associated with training increases the risk of pacemaker implantation without affecting mortality risk. [Extracted from the article]

Researchers at Mayo Clinic have reported on a case involving a 45-year-old female with advanced heart failure and ventricular arrhythmias. The patient received treatment including antiarrhythmic medications, inotrope support, diuretics, and the placement of an Impella 5.5 device for mechanical circulatory support. Due to persistent ventricular tachycardia, a bilateral stellate ganglion blockade was performed along with intensified antiarrhythmic therapy and deep sedation. The case highlights the potential benefits of combining mechanical circulatory support with stellate ganglion blockade in managing malignant ventricular arrhythmias. [Extracted from the article]

A new study from the Division of Cardiology at a university explores the use of wearable devices by patients with atrial fibrillation (AF) for symptom monitoring and health management. The study found that wearable users reported higher rates of symptom monitoring and preoccupation, as well as more concerns about AF treatment. They also had higher rates of AF-specific health care use, including more tests and procedures, and were more likely to use informal health care resources. The study suggests that further research is needed to understand the overall effects of wearables on patients, providers, and the health care system. [Extracted from the article]

A patent application has been submitted for a wearable ambulatory medical device that aims to improve the detection and treatment of cardiac conditions in ambulatory patients. The device includes multiple ECG sensing electrodes positioned at different locations on the patient's body, allowing for better signal quality and reducing false alarms. It can be integrated into a garment worn by the patient and includes a monitoring circuit to analyze the signals and select the most suitable electrodes to monitor based on various factors. The device also includes therapy electrodes and an arrhythmia detection circuit to initiate treatment if necessary. [Extracted from the article]

A patent application has been submitted for a new ablation system that uses pulmonary vein pressure sensing and display to treat cardiac arrhythmias. The system includes a cryogenic balloon catheter that is placed against the ostium of the pulmonary vein to block blood flow and deliver cryogenic fluid to create tissue necrosis. The patent application describes various components of the system, including a pressure sensor, a pump, a graphical display, and a control system. The goal of the system is to improve the accuracy and effectiveness of the ablation procedure by monitoring pulmonary vein pressure and displaying pressure waveforms and other operating parameters. The patent application was filed in January 2024. [Extracted from the article]

A patent application has been published online for a wearable medical device that monitors and treats heart conditions. The device includes a detachable rechargeable battery and is designed to alert the user when the battery is removed. It also has features such as monitoring for battery insertion into a charger and adjusting the alert frequency. This article provides reliable information about the patent application and its potential benefits for managing heart disorders, making it a valuable resource for library patrons researching health and medicine topics. [Extracted from the article]

A patent application has been filed for a new wearable cardioverter defibrillator (WCD) system that measures a patient's respiration. The WCD system includes a support structure, an energy storage module, a discharge circuit, an electrocardiogram (ECG) sensor, and other sensors to monitor patient characteristics. The system uses the ECG data and impedance signal to determine if a shock criterion is met, and if so, it discharges an electrical charge through the patient. The WCD system has the potential to accurately determine if a patient requires defibrillation therapy, such as sudden cardiac arrest, by combining the breathing characteristic with other data. [Extracted from the article]

A recent study conducted at MedStar Washington Hospital Center examined the impact of cardiac resynchronization therapy (CRT) on patients who received a durable left ventricular assist device (LVAD) implantation. The researchers found that there is no consensus on postoperative management for patients with preoperative CRT. The study revealed that patients with preoperative CRT who had it turned "on" after LVAD implantation had a significantly increased risk of mortality compared to those with preoperative CRT turned "off." However, there was no significant difference in the incidence of ventricular arrhythmias between patients with and without postoperative CRT. The researchers concluded that further clinical trials are needed to determine the best CRT programming strategy following LVAD implantation. [Extracted from the article]

A recent study from the University of Montreal explores innovative approaches to predicting atrial fibrillation (AF), a type of cardiac arrhythmia. The researchers discuss the potential benefits of using polygenic scores and machine learning in clinical practice to improve AF prediction and screening. They highlight the importance of identifying and predicting clinically relevant AF, considering factors such as family history and genetic markers. The integration of these novel approaches could enhance AF screening and personalize patient management. However, the study acknowledges current limitations and the need for further improvement in these modalities. [Extracted from the article]

A study conducted at Far Eastern Memorial Hospital compared the incidence of hypotension, bradycardia, and hypoxia between the use of remimazolam and other sedative agents during colonoscopy procedures. The researchers conducted a literature search and analyzed seven randomized control trials. The results showed no significant difference in the incidence of hypotension, bradycardia, or hypoxia when comparing remimazolam with other agents. However, when comparing remimazolam with propofol, there were statistically significant differences in the incidence of hypotension and bradycardia. The study suggests that remimazolam may have advantages over propofol in terms of hemodynamic changes during colonoscopy procedures. [Extracted from the article]

A recent study from Northwestern University Feinberg School of Medicine explores the diagnosis and management of atrial fibrillation (AF). The research emphasizes the importance of early detection in reducing adverse cardiovascular outcomes. The study highlights the development of device-monitoring technologies that can detect AF or AF-surrogates, leading to increased recognition of subclinical AF. The research also discusses different strategies for maintaining sinus rhythm and stroke prevention, such as catheter ablation and left atrial appendage occlusion. Overall, this study provides valuable insights into the controversies surrounding the diagnosis and management of AF. [Extracted from the article]